Rapiblyk Injection, Powder, Lyophilized, For Solution
NDC 84381-110
Product Information
Rapiblyk (landiolol) is a NDA-approved product labeled by Aop Orphan Pharmaceuticals Gmbh. This medication is typically used as a adrenergic beta1-antagonists [moa]. It is supplied as a injection, powder, lyophilized, for solution for intravenous administration. This product entry covers the primary NDC 84381-110 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 84381-110?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LANDIOLOL HYDROCHLORIDE (UNII: G8HQ634Y17)
- LANDIOLOL (UNII: 62NWQ924LH) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- MANNITOL (UNII: 3OWL53L36A)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2712074 - landiolol 280 MG Injection
- RxCUI: 2712074 - landiolol 280 MG (equivalent to landiolol HCl 300 MG) Injection
- RxCUI: 2712079 - Rapiblyk 280 MG Injection
- RxCUI: 2712079 - landiolol 280 MG Injection [Rapiblyk]
- RxCUI: 2712079 - Rapiblyk 280 MG (equivalent to landiolol HCl 300 MG) Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.